Kane Biotech Inc. (CVE:KNE – Get Free Report)’s stock price fell 28.6% during mid-day trading on Thursday. The company traded as low as C$0.03 and last traded at C$0.03. 231,000 shares changed hands during mid-day trading, an increase of 52% from the average daily volume of 151,812 shares. The stock had previously closed at C$0.04.
Kane Biotech Stock Performance
The company has a current ratio of 0.61, a quick ratio of 0.39 and a debt-to-equity ratio of -197.52. The company has a market cap of C$5.13 million, a P/E ratio of -1.25 and a beta of 0.79. The company has a 50 day moving average price of C$0.03 and a 200-day moving average price of C$0.03.
About Kane Biotech
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
Featured Articles
- Five stocks we like better than Kane Biotech
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
- Constellation Energy’s Nuclear Expansion Gets a $5 Billion Opening, Not a Guarantee
- Plugging In: Vertiv Cashes In On AI Demand
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
